In separate live virtual events, James K. McCloskey II, MD, and Bart L. Scott, MD, polled participants on disease symptoms and bridging therapy options for a patient with primary myelofibrosis (PMF).
CASE SUMMARY
A man aged 62 years presented to his primary care physician (PCP) with symptoms of fatigue, night sweats, and increased bruising .
Medical history: type 2 diabetes, hypercholesterolemia, and hypertension
The PCP noticed lower hemoglobin concentration (11.0-9.5 g/dL) and platelet count (350,000-195,000/μL) from a previous annual physical examination.
Two months post PCP visit, a hematologic oncologist saw him.
Examination findings: spleen 5 cm below left costal margin, fatigue and night sweats worsening, bone pain
Hemoglobin: 9.1 g/dL
Platelet count: 135,000/μL
Bone marrow fibrosis of grade 2/3, with less than 5% bone marrow blasts
Molecular analysis showed a JAK2 V617F mutation with normal karyotype and no additional mutations .
He had a history of squamous cell carcinoma of the skin .
ECOG performance status: 2
Blood: 1% blasts by manual count/flow cytometry
Diagnosis: PMF
Peers Discuss Sacituzumab Govitecan in HR+ mBC Post Endocrine Therapy
July 24th 2024During a Case-Based Roundtable® event, Tiffany A. Traina, MD, surveyed participants on treatment for a patient who had progressed following endocrine therapy for metastatic breast cancer in the first article of a 2-part series.
Read More
Leon-Ferre Explores Targeting of PIK3CA Alterations in ER+ Breast Cancer
July 24th 2024During a live Community Case Forum event in partnership with the Minnesota Society of Clinical Oncology, Roberto A. Leon-Ferre, MD, discussed drugs targeting PIK3CA alterations in patients with ER+ metastatic breast cancer.
Read More